Patents Assigned to Emory University
  • Patent number: 9980936
    Abstract: The disclosure relates to BH4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: May 29, 2018
    Assignees: Emory University, The Board of Regents of the University of Texas System
    Inventors: Xingming Deng, Jia Zhou, Chunyong Ding
  • Patent number: 9975868
    Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 22, 2018
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Patent number: 9962423
    Abstract: This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 8, 2018
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Andrew S Neish, Julie A Champion
  • Publication number: 20180121600
    Abstract: Methods, systems and computer-readable storage media relate to generating one or more consensus sequences. The methods may include determining a group of one or more reads with each main position without diversity from a group of one or more aligned reads based on diversity status of each main position, each group including sequence data disposed at a plurality of main positions and a plurality of secondary position regions disposed adjacent to the main positions. The methods may also include determining legitimate sequence data from each second position region having one or more nucleotides for each group of one or more reads without diversity; and generating a consensus sequence including sequence data disposed at each main position without diversity and legitimate sequence data disposed at each secondary position region for each group of one or more reads with each main position without diversity.
    Type: Application
    Filed: August 27, 2015
    Publication date: May 3, 2018
    Applicant: Emory University
    Inventors: Dario A. Dilernia, Jung-Ting Chien, Eric Hunter
  • Patent number: 9957300
    Abstract: Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (VLP) can include a viral core protein that can self assemble into the VLP core and at least one viral surface envelope glycoprotein expressed on the surface of the VLP. The VLP can also optionally include at least one adjuvant molecule expressed on the surface of the VLP.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 1, 2018
    Assignee: Emory University
    Inventors: Richard W. Compans, Chinglai Yang, Qizhi Yao, Sang-moo Kang
  • Patent number: 9944901
    Abstract: Provided is a protein coded by a gene related to cell totipotency and a transcriptional activation domain of a mammalian YAP protein or a fusion protein of a segment with a transcriptional control activity, a coding nucleotide sequence, an expression vector and a composition thereof, as well as a method for inducing the pluripotent stem cells by using the fusion protein.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: April 17, 2018
    Assignees: Institute of Zoology, Chinese Academy of Sciences, Emory University School of Medicine
    Inventors: Dahua Chen, Peng Jin, Qinmiao Sun, Weiqi Tan
  • Patent number: 9932326
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 3, 2018
    Assignees: Cocrystal Pharma, LLC, Emory University
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Patent number: 9932344
    Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 3, 2018
    Assignees: Cancer Research Technology Limited, Imperial Innovations Limited, Emory University
    Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
  • Patent number: 9932585
    Abstract: This disclosure relates to manipulating microRNA for the management of neurological disorders and compositions related thereto. In certain embodiments, the disclosure contemplates inhibition of miR324 or miR324-5p, e.g., the use of nucleobase polymers for antisense disruptions or RNA interference of miR-324 expression or for miR324-5p binding in order to increase Kv4.2 expression. In certain embodiments, the disclosure relates to methods of treating or preventing a neurological disease or condition comprising administering an effective amount of an inhibitor to a subject in need thereto.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: April 3, 2018
    Assignee: Emory University
    Inventors: Gary J. Bassell, Xiaodi Yao, Christina Gross
  • Patent number: 9932317
    Abstract: This invention relates to quinazoline compounds of Formula (I) which are inhibitors of the histone lysine methyltransferase (HKMTase) EZH2, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of EZH2 provides a therapeutic or prophylactic effect.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: April 3, 2018
    Assignees: Imperial Innovations Limited, Emory University
    Inventors: Robert Brown, Matthew John Fuchter, Nadine Chapman-Rothe, Nitipol Srimongkolpithak, Joachim Caron, James Snyder, Thota Ganesh, Jin Liu, Aiming Sun
  • Patent number: 9926295
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: March 27, 2018
    Assignees: Cocrystal Pharma, Inc., Emory University
    Inventors: Steven J. Coats, Richard Anthony Whitaker, Tamara Rosario McBrayer, Junxing Shi, Franck Amblard, Hongwang Zhang, Longhu Zhou, Raymond F. Schinazi
  • Patent number: 9926359
    Abstract: This disclosure relates to recombinant proteins, vectors, and methods of treating neurological conditions by exposing neurons to an opsin and luciferase in the presence of a luciferin. In certain embodiments, the disclosure relates to treating or preventing epilepsy or seizures comprising administering an effective amount of a vector that encodes an opsin and luciferase in combination with a luciferin to a subject in need thereof.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: March 27, 2018
    Assignee: Emory University
    Inventors: Robert E. Gross, Nealan G. Laxpati, Jack Tung, Ken Berglund
  • Patent number: 9919163
    Abstract: Methods, systems and computer-readable storage media relate to determining optimal treatment information. The methods may include determining a dose distribution for one or more target regions by applying a deformation parameter to a treatment plan dose distribution for a subset of a plurality of phases. The method may also include determining one or more dose parameters based on the dose distribution for the subset of the plurality of phases. The one or more dose parameters may represent a motion of the dose distribution over the plurality of phases for each region. The method may further include determining optimal treatment information based on the one or more dose parameters. The optimal treatment information may include optimal phase and associated dose distribution and the optimal phase may be a phase having a minimum total dose for the one or more target regions.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 20, 2018
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Mohammad Khurram Khan, Jerome Landry, Lei Zhu
  • Patent number: 9907797
    Abstract: This disclosure relates to the uses of compounds that target an interaction between CHFR and PARP1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits CHFR and PARP1 interactions, such as 5-((1-benzyl-1H-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: March 6, 2018
    Assignee: Emory University
    Inventor: Johann C Brandes
  • Publication number: 20180052161
    Abstract: Disclosed herein are methods of detecting Plasmodium in a subject (for example, presence of Plasmodium parasite) by detecting the presence and/or amount of one or more metabolites in a sample from the subject. In some embodiments, the methods include detecting in the sample one or more metabolites listed in Table 1, Table 2, and/or Tables 5-8. The amount of the one or more metabolites in the sample is compared to the amount of the one or more metabolites in a control and presence of Plasmodium is determined if the amount of the one or more metabolites is different (for example statistically significantly increased or decreased) compared to the control.
    Type: Application
    Filed: March 16, 2016
    Publication date: February 22, 2018
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Emory University
    Inventors: Ya Ping Shi, Laurence Slutsker, Youngja Park, Dean P. Jones, Loukia Lili-Williams
  • Patent number: 9884815
    Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 6, 2018
    Assignee: Emory University
    Inventors: Jing Chen, Taro Hitosugi, Sumin Kang
  • Patent number: 9877697
    Abstract: Systems, methods, and computer-readable storage media relate to generate an integrated image based on one or more applicators inserted into a target of a patient. The method may include receiving ultrasound image data and planning image data of the target. The ultrasound image data including a pre-operative and post-operative image data and the planning image data may include post-operative image data (e.g., CT and/or MRI image data). The method may include processing the ultrasound image data and the planning image data to determine a location of each channel and/or needle. The method may include generating an integrated image including the ultrasound image data and the planning image data based on the location of each channel and/or needle of the applicator. The methods, systems, and computer readable media according to embodiments can improve target (e.g., prostate) delineation, enable accurate dose planning and delivery, and potentially enhance HDR treatment outcome.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 30, 2018
    Assignee: Emory University
    Inventors: Xiaofeng Yang, Tian Liu, Peter J. Rossi
  • Patent number: 9872834
    Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 23, 2018
    Assignees: Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
    Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
  • Patent number: 9872895
    Abstract: The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: January 23, 2018
    Assignee: Emory University
    Inventors: Andrew T. Gewirtz, Benyue Zhang
  • Patent number: 9868728
    Abstract: The invention relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the invention relates to inhibitors of NADPH-oxidase.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 16, 2018
    Assignee: Emory University
    Inventors: John David Lambeth, Thota Ganesh, Susan M. Smith, Aiming Sun